$26.39
1.20% yesterday
Nasdaq, Aug 11, 10:02 pm CET
ISIN
US88322Q1085
Symbol
TGTX

TG Therapeutics, Inc. Stock price

$26.39
-10.70 28.84% 1M
-4.72 15.17% 6M
-3.71 12.33% YTD
+5.74 27.80% 1Y
+18.87 250.93% 3Y
+7.91 42.76% 5Y
+10.28 63.81% 10Y
-3,657.99 99.28% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.32 1.20%
ISIN
US88322Q1085
Symbol
TGTX
Industry

Key metrics

Basic
Market capitalization
$4.2b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
71.3 | 33.6
P/S
9.2 | 7.0
EV/Sales
- | 7.0
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
38.5%
Return on Equity
10.5%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$454.1m | $605.4m
EBITDA
- | $149.5m
EBIT
$85.8m | $149.7m
Net Income
$60.5m | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
31.0% | 84.0%
EBITDA
- | 256.1%
EBIT
-15.7% | 257.0%
Net Income
-36.8% | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
87.0%
EBITDA
- | 24.7%
EBIT
18.9%
Net
13.3% | -
Free Cash Flow
-
More
EPS
$0.4
FCF per Share
-
Short interest
19.9%
Employees
338
Rev per Employee
$970.0k
Show more

Is TG Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

TG Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a TG Therapeutics, Inc. forecast:

12x Buy
80%
2x Hold
13%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a TG Therapeutics, Inc. forecast:

Buy
80%
Hold
13%
Sell
7%

Financial data from TG Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
454 454
31% 31%
100%
- Direct Costs 59 59
136% 136%
13%
395 395
23% 23%
87%
- Selling and Administrative Expenses 187 187
36% 36%
41%
- Research and Development Expense 122 122
48% 48%
27%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 86 86
16% 16%
19%
Net Profit 60 60
37% 37%
13%

In millions USD.

Don't miss a Thing! We will send you all news about TG Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TG Therapeutics, Inc. Stock News

Neutral
The Motley Fool
8 days ago
TG Therapeutics Q2 Revenue Up 91%
Negative
Investors Business Daily
8 days ago
TG Therapeutics stock crashed Monday after the drugmaker reported in-line sales of Briumvi, but missed second-quarter profit expectations.
Neutral
Seeking Alpha
8 days ago
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Adam Waldman - Chief Commercialization Officer Jenna Bosco - Senior Vice President of Corporate Communications Michael S. Weiss - Chairman, CEO & President Sean A.
More TG Therapeutics, Inc. News

Company Profile

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Head office United States
CEO Michael Weiss
Employees 338
Founded 1993
Website www.tgtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today